XNCR
Xencor Inc

724
Loading...
Loading...
News
all
press releases
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·16d ago
News Placeholder
More News
News Placeholder
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +47.44% and +116.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
chainwire·5mo ago
News Placeholder
Xencor Reports Third Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for...
Business Wire·11mo ago
News Placeholder
Xencor Doses First Subject in Phase 1/2 Study of XmAb942 in Development for Patients with Inflammatory Bowel Disease
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated...
Business Wire·11mo ago
News Placeholder
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that preclinical data...
Business Wire·1y ago
News Placeholder
Xencor Announces Upcoming Change to Board of Directors
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar...
Business Wire·1y ago
News Placeholder
Xencor Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Latest Ratings for XNCR DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Feb 2022BMO CapitalInitiates Coverage OnOutperform Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy View...
Benzinga·1y ago
News Placeholder
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
Xencor, Inc. (Xencor) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing...
Business Wire·1y ago

Latest XNCR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.